(160) Development of the Analgesic Adverse Drug Response Measure

Abstract

The purpose was to develop a measure of how people respond to an analgesic adverse drug event in an effort to increase safe analgesic use. A two-phase methodological design was used to develop and test the Analgesic Adverse Drug Response Measure. During phase I a panel of 6 experts rated 58 items developed from a pilot with adults who had experienced an analgesic adverse drug response (ADR). Items with a content validity index (CVI)=.83 or greater were retained. The final measure consisted of 17 items, CVI=.86. During phase II an online survey was conducted with a national Qualtrics panel of 292 adults who reported an ADR from a self-administered analgesic. Additional descriptive measures included demographics and description of the ADR and co-morbidities. The factor analysis is pending. Analgesics most frequently associated with an ADR included hydrocodone (23.6%), codeine (19.5%), and ibuprofen (14.0%). The majority reported that they were the first person to notice the ADR (93.8%) and identified the ADR within an hour of taking the analgesic (59.6%). The most frequent ADRs included nausea (31.2%), abdominal pain (15.4%), vomiting (14.0%), and dizziness (10.3%). Potentially life-threatening symptoms included gastrointestinal bleeding (3.1%) and anaphylaxis (2.1%). A total of 73.3% talked with their provider or pharmacist (28.0%) about the ADR. Twenty-four percent continued to take the analgesic despite the ADR. High risk groups who continue to take ADR associated analgesics and/or who do not consult with their provider about the ADR should be examined so that tailored risk reduction interventions can be developed. Our pending factor analysis will contribute to the construct validity of the Analgesic Adverse Drug Response Measure and use of the Analgesic Adverse Drug Response Measure to identify at risk groups and behaviors associated with analgesic ADRs.